Literature DB >> 18348909

Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR.

Evelyn Oliveira Machado1, Giselle F Taboada, Leonardo Vieira Neto, Flávia R van Haute, Lívia L Corrêa, Giovanna A Balarini, Yolanda Shrank, Marcio Goulart, Mônica R Gadelha.   

Abstract

BACKGROUND: Acromegalic patients are considered "discordant" if their insulin-like growth factor type I (IGF-I) levels are increased for their age with "safe" growth hormone (GH) levels or if their IGF-I levels are normal for their age with "unsafe" GH levels. The prevalence of discordance in acromegalics has been described to vary from 9.4% to 39%, and it may be observed at diagnosis or during the follow up.
OBJECTIVE: To evaluate the prevalence of discordant levels of IGF-I and GH in our acromegalic population.
METHODS: Hormonal evaluation was made with an oral glucose tolerance test (OGTT) with the IGF-I being assessed in the basal sample at diagnosis and after 3 months of the adenomectomy. During treatment with octreotide LAR, a GH curve (for the calculation of mean GH) and IGF-I assessment were made every 3 months.
RESULTS: Among the 51 patients evaluated at diagnosis, the prevalence of discordance was 13.7% (7/51). Among the 58 patients evaluated after the surgical procedure, eight (13.8%) had discordant GH and IGF-I levels. Among the 42 patients evaluated during treatment with octreotide LAR, the prevalence of discordant GH and IGF-I levels was 33.3% (14/42). Using 1 microg/L as a cut off level for "safe" GH, the prevalence of discordance was 3.9%, 8.6% and 28.6% at diagnosis, after surgery and during treatment with octreotide LAR, respectively. No difference of sex, age or treatment modality was observed among discordant and concordant patients with any GH cut off level.
CONCLUSION: We observed a prevalence of discordance similar to that previously described in the literature. We believe that studies evaluating morbidity and mortality in discordant patients are also necessary and will enlighten the true impact of this condition in the follow up of acromegaly.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18348909     DOI: 10.1016/j.ghir.2008.02.001

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  20 in total

1.  Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission.

Authors:  Samuel S Shin; Matthew J Tormenti; Alessandro Paluzzi; William E Rothfus; Yue-Fang Chang; Hanady Zainah; Juan C Fernandez-Miranda; Carl H Snyderman; Sue M Challinor; Paul A Gardner
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

2.  Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?

Authors:  Jessica A Brzana; Chris G Yedinak; Johnny B Delashaw; Hume S Gultelkin; David Cook; Maria Fleseriu
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

3.  Matrix metalloproteinase 2 (MMP-2) levels are increased in active acromegaly patients.

Authors:  Alper Cagri Karci; Zeynep Canturk; Ilhan Tarkun; Berrin Cetinarslan
Journal:  Endocrine       Date:  2017-03-22       Impact factor: 3.633

4.  Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy.

Authors:  Yasuyuki Kinoshita; Atsushi Tominaga; Satoshi Usui; Kazunori Arita; Tetsuhiko Sakoguchi; Kazuhiko Sugiyama; Kaoru Kurisu
Journal:  Neurosurg Rev       Date:  2016-01-20       Impact factor: 3.042

Review 5.  Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.

Authors:  Federico Gatto; Claudia Campana; Francesco Cocchiara; Giuliana Corica; Manuela Albertelli; Mara Boschetti; Gianluigi Zona; Diego Criminelli; Massimo Giusti; Diego Ferone
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

6.  Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients.

Authors:  Laura Boero; Marcos Manavela; Karina Danilowicz; Analia Alfieri; Maria Carolina Ballarino; Alberto Chervin; Natalia García-Basavilbaso; Mariela Glerean; Mirtha Guitelman; Monica Graciela Loto; Jose Alberto Nahmías; Amelia Susana Rogozinski; Marisa Servidio; Nicolas Marcelo Vitale; Débora Katz; Patricia Fainstein Day; Graciela Stalldecker; Maria Susana Mallea-Gil
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

7.  Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.

Authors:  Giuseppe Reimondo; Marta Bondanelli; Maria Rosaria Ambrosio; Franco Grimaldi; Barbara Zaggia; Maria Chiara Zatelli; Barbara Allasino; Federica Laino; Emiliano Aroasio; Angela Termine; Pierantonio Conton; Agostino Paoletta; Ernesto Demenis; Ettore Degli Uberti; Massimo Terzolo
Journal:  Endocrine       Date:  2013-06-21       Impact factor: 3.633

8.  SOCS2 polymorphisms are not associated with clinical and biochemical phenotypes in acromegalic patients.

Authors:  Ericka B Trarbach; Alexander A Jorge; Felipe H Duarte; Marcello D Bronstein; Raquel S Jallad
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

Review 9.  Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?

Authors:  Pamela U Freda
Journal:  Clin Endocrinol (Oxf)       Date:  2009-02-18       Impact factor: 3.478

10.  Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.

Authors:  Roberto Salvatori; Lisa B Nachtigall; David M Cook; Vivien Bonert; Mark E Molitch; Sandra Blethen; Stephen Chang
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.